ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO581

Treatment with Lanthanum Carbonate (LC) May Reduce Bone Mineral Density (BMD): Six-Year Observation in Hemodialysis (HD) Patients

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Hashiguchi, Jyunichiro, Nagasaki Kidney Center, Nagasaki, Japan
  • Funakoshi, Satoshi, Nagasaki Renal Center, Nagasaki, Japan
  • Sawase, Kenji, Nagasaki Kidney Center, Nagasaki, Japan
  • Kawazu, Tayo, Nagasaki Kidney Center, Nagasaki, Japan
  • Kubara, Takuya, Nagasaki Kidney Center, Nagasaki, Japan
  • Hayashida, Masatoshi, Nagasaki Renal Center, Nagasaki, Japan
  • Miyazaki, Sayaka, Nagasaki Kidney Center, Nagasaki, Japan
  • Ide, Mashumi, Nagasaki Kidney Center, Nagasaki, Japan
  • Nishino, Tomoya, Nagasaki University School of Medicine, Nagasaki, NAGASAKI, Japan
  • Harada, Takashi, Nagasaki Kidney Center, Nagasaki, Japan
Background

LC is one of the most powerful phosphate binders (PB) for the treatment of hyperphosphatemia in HD patients. However, whether LC can increase BMD or not is still controversial. This study was performed to examine the effects of LC on alteration of BMD in HD patients.

Methods

Subjects were divided into 2 groups and compared. Group 1: Twenty-two HD patients who were treated with non-LC PB for 6 years (14 males and 8 females; mean age, 66.7±7.4 years old; mean HD duration, 11.4±7.6 years). Group 2: Fourteen HD patients who were treated non-LC PB for 3 years, then were converted to receive LC for 3 years (5 males and 9 females; mean age, 62.7±5.5 years old; mean HD duration, 9.7±6.6 years). BMD in these patients were estimated by digital image processing (DIP).

Results

As shown in Figure, the alteration ratio in BMD for group1 was -1.6% / year over 6 years, whereas the alteration ratio was -2.0% / year in the former 3 years, then declined to -7.9% / year in the latter 3 years in group 2. The decrease ratio of BMD for group 2 at 6 years was significantly lower than that of group 1 (p<0.05).

Conclusion

The decline of BMD was constant through 6 years in group 1; whereas the decline of BMD was accelerated after the treatment was converted from non-LC PB to LC in group 2. These observations suggest that administration of LC may reduce BMD in HD patients for some mechanisms.

Funding

  • Private Foundation Support